By Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop ...
NS fans turn up for Crosby's homecoming | SaltWireJERUSALEM - Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately be a blockbuster drug.
Clinical 3 trials are not expected to begin until 2025 and Teva CEO Richard Francis said the best case scenario for the drug's commercial launch would be around 2028. Under the terms of the deal, Teva will receive an upfront payment of $500 million in cash once the transaction closes, which is expected by the end of 2023, and up to $1 billion in development and launch milestones.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drugBy Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop ...
Lire la suite »
Cruise lines, spinoff slumps, Eli Lilly-Point deal: Trending StocksShares of cruise line stocks Carnival Corp. (CCL), Royal Caribbean (RCL), and Norwegian (NCLH) close lower on Tuesday as Morgan Stanley analysts slash their price targets, citing rising fuel costs in travel demand headwinds. Recently spun-off companies Vestis Corporation (VSTS), Veralto (VLTO), and WK Kellogg Co. (KLG) slide lower following their listing debuts. Lastly, pharmaceutical giant Eli Lilly (LLY) is set to acquire Point Biopharma (PNT) in a $1.4 billion deal. Yahoo Finance Live takes a closer look at several of Tuesday's trending stocks after the closing bell from the New York Stock Exchange. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Lire la suite »
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19STOCKHOLM (AP) — Two scientists won the Nobel Prize in medicine on Monday for discoveries that enabled the creation of mRNA vaccines against COVID-19 that were critical in slowing the pandemic and whose technology could be used in the future to devel
Lire la suite »
Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drugBy Steven Scheer JERUSALEM (Reuters) - Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop ...
Lire la suite »
U.S. FDA declines to approve Eli Lilly's skin disease drug(Reuters) - The U.S. Food and Drug Administration has declined to approve Eli Lilly's drug to treat a type of skin disease due to certain findings ...
Lire la suite »
U.S. FDA declines to approve Eli Lilly's skin disease drug(Reuters) - The U.S. Food and Drug Administration has declined to approve Eli Lilly's drug to treat a type of skin disease due to certain findings ...
Lire la suite »